Polyclonal antibodies to KIT (western), MAPK, GAPDH and HSP90 were purchased from Dako (Carpinteria, CA), Life Technologies (Carlsbad, CA), Proteintech Group Inc. (Rosemont, IL) and Santa Cruz Biotechnology (Santa Cruz, CA), respectively. All phospho-antibodies, polyclonal antibodies to AKT and the monoclonal antibody to S6 were purchased from Cell Signaling Technology (Beverly, MA). Monoclonal mouse antibodies to KIT (co-IP) and CK2 (Santa Cruz Biotechnology, CA), CDC37 (Abcam Biotechnology, Cambridge, MA) and β-actin (Sigma-Aldrich, St. Louis, MO) were used. Anti-mouse normal IgG was purchased from Cell Signaling Biotechnology. CX4945 (CX) and imatinib (IM) were purchased from Selleck (Houston, TX) and LC Laboratories (Woburn, MA, USA), respectively. Lentiviral CK2 shRNA constructs were purchased from The RNAi Consortium (TRC, Cambridge, MA, USA). Crystal violet and propidium iodide solution were purchased from Sigma-Aldrich. Protein A, Protein G beads, Lipofectamine and Plus reagent were purchased from Invitrogen (LIFE Technologies, USA). Puromycin and polybrene were purchased from Sigma (St. Louis, MO, USA).
Imatinib im
Manufactured by Selleck Chemicals
Sourced in United States
Imatinib (IM) is a small-molecule tyrosine kinase inhibitor. It functions by blocking the activity of certain enzymes involved in cell signaling pathways.
Automatically generated - may contain errors
Lab products found in correlation
Crystal violet, by Merck Group (1 mentions)
Plus reagent, by Thermo Fisher Scientific (1 mentions)
Lipofectamine, by Thermo Fisher Scientific (1 mentions)
Propidium iodide solution, by Merck Group (1 mentions)
Puromycin, by Merck Group (1 mentions)
Protein g beads, by Thermo Fisher Scientific (1 mentions)
β actin, by Merck Group (1 mentions)
Gapdh, by Agilent Technologies (1 mentions)
Cdc37, by Abcam (1 mentions)
2 protocols using imatinib im
1
Antibodies and Inhibitors for Protein Analysis
2
Imatinib, 17-DMAG, and Novobiocin Therapy
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
From day 10 after transplantation, the recipient mice were treated once daily with 50 mg/kg imatinib (IM) (S1026; Selleck) in 0.2 mL 0.5% CMC-Na (S6703; Selleck) or 0.5% CMC-Na as a control by gavage. The 17-DMAG was dissolved in 5% DMSO + 40% PEG300 + 5% Tween-80 + 50% water, and novobiocin was dissolved in water. The 17-DMAG (25 mg/kg) and novobiocin (100 mg/kg) were administered by intraperitoneal injection, once daily. The treatments were continued until the recipient mice were euthanized. The weight and appearance of the treated mice were monitored every other day and they were euthanized when they appeared moribund.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!